Humacyte annual r&d spending
2020
2021
2022
2023
2024
2025
Humacyte R&D Spending Growth & History (HUMA)
Humacyte's r&d spending was $69.3M for fiscal 2025.
View full Humacyte company overviewHumacyte annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $69.3M | −$19.3M | −21.78% |
| 2024 | 2024-12-31 | $88.6M | $12.0M | +15.74% |
| 2023 | 2023-12-31 | $76.5M | $13.3M | +21.01% |
| 2022 | 2022-12-31 | $63.3M | $1.9M | +3.13% |
| 2021 | 2021-12-31 | $61.3M | $7.3M | +13.43% |
| 2020 | 2020-12-31 | $54.1M | — | — |
Humacyte quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18.1M | −$3.9M | −17.55% |
| Q1 2026 | 2026-03-31 | $19.5M | $4.0M | +26.23% |
| Q4 2025 | 2025-12-31 | $14.6M | −$6.1M | −29.29% |
| Q3 2025 | 2025-09-30 | $17.3M | −$5.7M | −24.66% |
| Q2 2025 | 2025-06-30 | $22.0M | −$1.7M | −7.35% |
| Q1 2025 | 2025-03-31 | $15.4M | −$5.8M | −27.49% |
| Q4 2024 | 2024-12-31 | $20.7M | $476,000 | +2.36% |
| Q3 2024 | 2024-09-30 | $22.9M | $4.4M | +23.58% |
| Q2 2024 | 2024-06-30 | $23.8M | $3.2M | +15.64% |
| Q1 2024 | 2024-03-31 | $21.3M | $4.0M | +23.07% |
| Q4 2023 | 2023-12-31 | $20.2M | $5.2M | +34.92% |
| Q3 2023 | 2023-09-30 | $18.6M | $1.2M | +7.01% |
| Q2 2023 | 2023-06-30 | $20.5M | $5.9M | +40.19% |
| Q1 2023 | 2023-03-31 | $17.3M | $964,000 | +5.91% |
| Q4 2022 | 2022-12-31 | $15.0M | −$1.3M | −7.96% |
| Q3 2022 | 2022-09-30 | $17.3M | $2.0M | +12.68% |
| Q2 2022 | 2022-06-30 | $14.7M | $84,000 | +0.58% |
| Q1 2022 | 2022-03-31 | $16.3M | $1.2M | +7.78% |
| Q4 2021 | 2021-12-31 | $16.3M | — | — |
| Q3 2021 | 2021-09-30 | $15.4M | $694,000 | +4.72% |
| Q2 2021 | 2021-06-30 | $14.6M | — | — |
| Q1 2021 | 2021-03-31 | $15.1M | — | — |
| Q3 2020 | 2020-09-30 | $14.7M | — | — |
Humacyte r&d spending trends
Over the last five fiscal years, Humacyte's r&d spending increased from $54.1M to $69.3M, a change of $15.2M. The latest reported quarter, Q2 2026, shows $18.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Humacyte source filings ↗